Novel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact

Finch, 2005, Safety and efficacy of glycopeptide antibiotics, J Antimicrob Chemother, 55, ii5, 10.1093/jac/dki004 Steinkraus, 2007, Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA blood isolates from 2001–05), J Antimicrob Chemother, 60, 788, 10.1093/jac/dkm258 Gould, 2008, Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus, Int J Antimicrob Agents, 31, 1, 10.1016/S0924-8579(08)70002-5 Wilson, 2003, Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment, J Antimicrob Chemother, 52, 78, 10.1093/jac/dkg296 König, 2014, Quantification of vancomycin in human serum by LC-MS/MS, Clin Chem Lab Med, 51, 1761 Shipkova, 2014, Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring, Ther Drug Monit, 36, 433, 10.1097/FTD.0000000000000043 Diana, 2006, Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry, Rapid Commun Mass Spectrom, 20, 685, 10.1002/rcm.2364 Zhao, 2012, External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings, Br J Pharmacol, 75, 1068, 10.1111/j.1365-2125.2012.04406.x Zhao, 2013, The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results, Ther Drug Monit, 35, 416, 10.1097/FTD.0b013e3182866a99 Kullar, 2011, Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggest targets, Clin Infect Dis, 52, 975, 10.1093/cid/cir124 Rybak, 2009, Therapeutic drug monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am J Health Syst Pharm, 66, 82, 10.2146/ajhp080434 Mouton, 2008, Tissue concentrations: do we ever learn?, J Antimicrob Chemother, 61, 235, 10.1093/jac/dkm476 Lamer, 1993, Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients, Antimicrob Agents Chemother, 37, 281, 10.1128/AAC.37.2.281 Rybak, 2006, The pharmacokinetic and pharmacodynamic properties of vancomycin, Clin Infect Dis, 42, S35, 10.1086/491712 Cass, 2001, Rapid bioanalysis of vancomycin in serum and urine by high-performance liquid chromatography tandem mass spectrometry using on-line sample extraction and parallel analytical columns, Rapid Commun Mass Spectrom, 15, 406, 10.1002/rcm.246 Zhang, 2007, Determination of vancomycin in serum by liquid chromatography-high resolution full scan mass spectrometry, J Chromatogr B, 857, 352, 10.1016/j.jchromb.2007.07.041 Shibata, 2003, Highly sensitive quantification of vancomycin in plasma samples using liquid chromatography–tandem mass spectrometry and oral bioavailability in rats, J Chromatogr B, 787, 211, 10.1016/S1570-0232(03)00068-0 Bijleveld, 2014, A simple quantitative method analyzing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study, J Chrom B, 951, 110, 10.1016/j.jchromb.2014.01.035 CLSI, 2004, Evaluation of precision performance of quantitative measurement methods; approved guideline—second edition 2011 CLSI, 2007, Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline 2012 2013 2012 2012 Bland, 1986, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet, 1, 307, 10.1016/S0140-6736(86)90837-8 Passing, 1983, A new biometrical procedure for testing equality of measurements from two different analytical methods, J Clin Chem Clin Biochem, 21, 709 Ezan, 1997, Effect of variability of plasma interferences on the accuracy of drug immunoassays, Ther Drug Monit, 19, 212, 10.1097/00007691-199704000-00017 LeGatt, 2012, The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals, Ther Drug Monitr, 34, 306, 10.1097/FTD.0b013e318257335f Azzazy, 1998, Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies, Ther Drug Monit, 20, 202, 10.1097/00007691-199804000-00011